Abstract
The therapeutic options available for the management of malignant pleural effusions associated with a restricting malignant cortex remain unsatisfactory. The efficacy of pleuroperitoneal shunts was evaluated in 16 patients with recurrent malignant effusions. There were no operative deaths; one patient died on the third postoperative day as a result of lymphangitis carcinomatosa. The median hospital stay was five (range 3-21) days. Palliation was obtained in all but one of the other 15 patients. There was no appreciable reaccumulation of pleural fluid as judged by radiography. Two patients developed occlusion of the shunt. In one case this was due to blood clots in the pleural catheter and necessitated insertion of a new shunt. The other shunt was removed because of obstructing infected fibrin debris, and a rib resection was performed. There were eight deaths related to the underlying malignancy after a mean interval of 7.3 (range 1.5-23) months. The other six patients are still alive, with a mean survival of 11.0 (range 5-20) months, and have achieved good symptomatic relief. The insertion of a pleuroperitoneal shunt can offer effective palliation for patients with recurrent malignant pleural effusions.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Anderson C. B., Philpott G. W., Ferguson T. B. The treatment of malignant pleural effusions. Cancer. 1974 Apr;33(4):916–922. doi: 10.1002/1097-0142(197404)33:4<916::aid-cncr2820330405>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
- Cimochowski G. E., Joyner L. R., Fardin R., Sarama R., Maran A. Pleuroperitoneal shunting for recalcitrant pleural effusions. J Thorac Cardiovasc Surg. 1986 Nov;92(5):866–870. [PubMed] [Google Scholar]
- Fentiman I. S. Effective treatment of malignant pleural effusions. Br J Hosp Med. 1987 May;37(5):421, 424-8. [PubMed] [Google Scholar]
- Martini N., Bains M. S., Beattie E. J., Jr Indications for pleurectomy in malignant effusion. Cancer. 1975 Mar;35(3):734–738. doi: 10.1002/1097-0142(197503)35:3<734::aid-cncr2820350328>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
- Milsom J. W., Kron I. L., Rheuban K. S., Rodgers B. M. Chylothorax: an assessment of current surgical management. J Thorac Cardiovasc Surg. 1985 Feb;89(2):221–227. [PubMed] [Google Scholar]
- Pollock A. V. The treatment of resistant malignant ascites by insertion of a peritoneo-atrial Holter valve. Br J Surg. 1975 Feb;62(2):104–107. doi: 10.1002/bjs.1800620206. [DOI] [PubMed] [Google Scholar]
- Tarin D., Price J. E., Kettlewell M. G., Souter R. G., Vass A. C., Crossley B. Clinicopathological observations on metastasis in man studied in patients treated with peritoneovenous shunts. Br Med J (Clin Res Ed) 1984 Mar 10;288(6419):749–751. doi: 10.1136/bmj.288.6419.749. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Weese J. L., Schouten J. T. Pleural peritoneal shunts for the treatment of malignant pleural effusions. Surg Gynecol Obstet. 1982 Mar;154(3):391–392. [PubMed] [Google Scholar]